Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorWISLEZ, M.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorDOMBLIDES, Charlotte
dc.contributor.authorGREILLIER, L.
dc.contributor.authorMAZIERES, J.
dc.contributor.authorMONNET, I.
dc.contributor.authorKIAKOUAMA-MALEKA, L.
dc.contributor.authorQUANTIN, X.
dc.contributor.authorSPANO, J.P.
dc.contributor.authorRICORDEL, C.
dc.contributor.authorFRAISSE, P.
dc.contributor.authorJANICOT, H.
dc.contributor.authorAUDIGIER-VALETTE, C.
dc.contributor.authorAMOUR, E.
dc.contributor.authorLANGLAIS, A.
dc.contributor.authorRABBE, N.
dc.contributor.authorMAKINSON, A.
dc.contributor.authorCADRANEL, J.
dc.contributor.authorLAURENT-PUIG, P.
dc.contributor.authorLAVOLE, A.
dc.contributor.authorBLONS, H.
dc.date.accessioned2022-05-02T16:02:57Z
dc.date.available2022-05-02T16:02:57Z
dc.date.issued2021-05-13
dc.identifier.issn0169-5002en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/139960
dc.description.abstractEnIntroduction: HIV is an exclusion criterion for most lung cancer (LC) trials, however LC is the most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer prognosis than the general population. Circulating tumor DNA (ctDNA) was a prognostic marker in LC patients from the general population. This study assessed ctDNA's prognostic value in PLHIV from a dedicated phase II trial. Methods: Overall, 61 PLHIV with advanced non-squamous non-small-cell lung cancer (NSCLC) participated in the IFCT Phase II trial evaluating first-line four-cycle carboplatin (Ca) AUC5 pemetrexed (P) 500 mg/m2 induction therapy every 3 weeks, followed by P maintenance therapy. Blood samples collected before treatment were analyzed to detect ctDNA using ultra-deep targeted next-generation-sequencing (NGS). Results: Appropriate samples were available from 55 PLVIH and analyzed for ctDNA detection. Including 42 males (76.4 %), 52.9 years median age, 51 smokers (92.7 %), five with non-squamous NSCLC Stage III (9%), 50 Stage IV (91 %), and performance status (PS) 0?2. ctDNA was detected in 35 patients (64 %), 22 with high and 13 with low ctDNA levels. Overall, 77 % were positive for TP53, 29 % for KRAS, and 11 % for STK11 mutations, more than one alteration was detected in 43 % of samples. Multivariate analysis showed that positive ctDNA was significantly associated with shorter PFS (HR, 4.31, 95 %CI: 2.06?8.99, p < 0.0001), and shorter OS (HR, 3.52, 95 %CI: 1.72?7.19, p < 0.001). Moreover, OS was significantly longer for patients with low ctDNA levels at diagnosis as compared to high (p = 0.01). Conclusion: We show that ctDNA detection using ultra-deep NGS is an independent prognostic factor in PLHIV with advanced NSCLC.
dc.language.isoENen_US
dc.subject.enCarboplatin
dc.subject.enCirculating tumor DNA
dc.subject.enHIV positivity
dc.subject.enNon-small-cell lung cancer
dc.subject.enPemetrexed
dc.title.enCirculating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.lungcan.2021.05.013en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed34016488en_US
bordeaux.journalLung Canceren_US
bordeaux.page124-130en_US
bordeaux.volume157en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Lung%20Cancer&rft.date=2021-05-13&rft.volume=157&rft.spage=124-130&rft.epage=124-130&rft.eissn=0169-5002&rft.issn=0169-5002&rft.au=WISLEZ,%20M.&DOMBLIDES,%20Charlotte&GREILLIER,%20L.&MAZIERES,%20J.&MONNET,%20I.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée